Neuromyelitis Optica Spectrum Disorder (Nmosd) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, China, Canada, India - Size and Forecast 2024-2028

Neuromyelitis Optica Spectrum Disorder Market Size 2024-2028

The neuromyelitis optica spectrum disorder market size is estimated to grow by USD 205.1 million at a CAGR of 6.78% between 2023 and 2028. The growing geriatric population is driving the market growth. NMOSD is an autoimmune demyelinating disease that involves demyelination of mostly the optic nerves and spinal cord and is primarily observed in the elderly population. According to the National Institutes of Health (NIH), it is more prevalent in people above 50 years of age. Some optical disorders that have a higher risk of development with age include cataracts, glaucoma, and dry eye syndrome.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by Application, Type, and Geography Analysis

Application Analysis

The market share growth by the hospitals segment will be significant during the forecast period, as indicated by market forecasting. Multi-specialty hospitals and private hospital groups that operate on government or private sponsorships work in close collaboration with medicine suppliers and government bodies to purchase medicines and consumables in bulk, reflecting market growth and trends.

Get a glance at the contribution of various segments View a PDF Sample

The hospitals segment was valued at USD 208.30 million in 2018. There are several mid-sized hospitals that work with local industries, have fewer hospital beds (200-300), and have a decentralized administration compared to multi-specialty hospitals, as observed in market trends and analysis. Additionally, they have skilled professionals and continuous treatment for symptomatic and curative treatment, contributing to market growth analysis. These factors will also propel the growth of the global neuromyelitis optica spectrum disorder market during the forecast period, aligning with market research and growth and market growth and forecasting. Hence, such factors are fuelling the growth of this segment during the forecast period.

Type Analysis

The growth of the with Aquaporin-4 (AQP4) antibodies segment, an antigen found in more than 75% of NSMOD patients. Patients with AQP4 antigens might have attacks of the AQP4 protein in the brain, spinal cord, and optic nerve. One of the drugs used to prevent relapsing NSMOD in these patients is Ecluzimab, a terminal complement inhibitor. Hence, drugs and treatment methods for the population with AQP4 antibodies are expected to result in the growth of the global neuromyelitis Optica spectrum disorder during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 38% to the growth of the global during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the during the forecast period. Within North America, the largest region in the global neuromyelitis Optica spectrum disorder, the US and Canada are the largest markets due to the presence of pharmaceutical giants in the region, and a higher prevalence rate of neuromyelitis Optica spectrum disorder. This has witnessed growth due to the growing geriatric population, increased screen time, and awareness of the condition and its treatment.

Additionally, numerous pharmaceutical companies are involved in the manufacture and sales of neuromyelitis optica spectrum disorder drugs in North America including Genetech and Viela bio. These factors are likely to boost the growth of the during the forecast period.

Buy Now Full Report and Discover More

Key Market Players 

industries are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence. The report also includes detailed analyses of the competitive landscape of the market and information about 9 key industries, including:

AstraZeneca - The company offers Ultomiris for the treatment of neuromyelitis optica spectrum disorder.

• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• F. Hoffmann La Roche Ltd.
• HBM Holdings Ltd.
• Horizon Therapeutics Plc
• TG Therapeutics Inc.
• Mitsubishi Chemical Group Corp.
• Opexa Therapeutics Inc.

Qualitative and quantitative analysis of industries has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key players. Data is qualitatively analyzed to categorize industries as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize industries as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune inflammatory condition that primarily affects the optic nerves and spinal cord. Aquaporin 4 antibodies are identified as the main cause of this disorder. The market for Neuromyelitis Optica Spectrum Disorder therapeutics is witnessing significant growth due to the increasing prevalence of the disease and the development of new treatments. Plasma exchange therapy and parenteral injections are common treatment methods for NMOSD. Monoclonal antibody drugs, such as Inebilizumab, Tocilizumab, and ULTOMIRIS, are gaining popularity due to their effectiveness in reducing relapses and preventing disability. Diagnosis of NMOSD can be challenging, and early diagnosis is crucial for effective treatment. Homecare and retail pharmacy are becoming preferred options for patients due to their convenience and affordability. Devic Disease, a form of NMOSD, can lead to paralysis and even premature death if left untreated. The European Medicines Agency has approved several monoclonal antibody drugs for the treatment of NMOSD, including Enspryng from Genentech. Corticosteroids and C5 protein inhibitors are also used in the treatment of NMOSD. The rising healthcare expenditures and insurance coverage for NMOSD treatments are expected to drive market growth. Healthcare professionals are emphasizing the importance of early diagnosis and effective treatment to improve patient outcomes. The ongoing COVID-19 pandemic may impact the market due to disruptions in supply chains and healthcare services.

Key Market Drivers

The growing geriatric population is driving the growth. NMOSD is characterized by demyelination of the optic nerves and spinal cord and is primarily found in the elderly population. Asia is a highly lucrative region for disorders like NSMOD due to its growing geriatric population.

However, North America and Europe hold the major shares in the owing to higher investments in the healthcare sector. Some age-related eye disorders include age-related macular degeneration (AMD), diabetic eye disease, and low vision. Additionally, the likelihood of developing dry eye syndrome increases with age due to reduced tear production. Hence, the above factors are likely to increase the demand for neuromyelitis Optica spectrum disorder drugs which will result in growth during the forecast period.

Significant Market Trends

Advances in the treatment of NMOSD is a key trend. Several prescriptions for the treatment of NMOSD are available with a varying range of drugs, mechanisms, and endpoints. Generally, they serve as the first line of therapy along with anti-coagulant medications, such as corticosteroids (glucocorticoid), azathioprinol, or RITUXIMAB for NMOSD patients. For and as the second line of treatment for NMOSD patients they are used in combination with immunosuppressants like Methotrexate and Mitoxantrone.

Additionally, there is research into refining existing strategies for the treatment of long-term disability and mortality associated with NMOSD with stem cell therapy being part of it. It gives various advantages including regulation of immune response and promoting local tissue repair and regeneration. This suggests there is a therapeutic potential of hUC-MSC to treat autoimmune disorders like NSMOD. Furthermore, research grants such as those done by the Sumaira Foundation in 2023 to provide nonprofit organizations, researchers, and institutions funds for research into prevention and treatments for NMOSD. Hence, the above factors are likely to increase the growth of the during the forecast period.

Major Market Challenges

The high costs of NMOSD treatment are challenging the growth. Due to the lack of proper treatment, treatment only helps sustain symptoms to a degree. Drugs prescribed include corticosteroids, azathioprine, and new immunosuppressive treatments, including eculizumab, satralizumab, and inebilizumab.

Moreover, they are usually very expensive, with the annual cost of taking four 300 mg vials of eculizumab every two weeks being approximately USD 400,000. Hence, the high costs of adhering to treatment prescriptions are likely to hinder the growth of the during the forecast period.

Buy Now Full Report and Discover More

Market Customer Landscape

The report includes the adoption lifecycle of the, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Market Customer Landscape

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.

• Application Outlook
  • Hospitals
  • Specialty clinics
  • Homecare

• Type Outlook
  • With aquaporin-4 antibodies
  • Without aquaporin-4 antibodies

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Australia
    • Argentina
    • Brazil

You may also interested in below market reports:

Apheresis Devices Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast

Autism Spectrum Disorder Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, Canada, China - Size and Forecast

Bipolar Disorder Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast

Market Analyst Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune disorder that attacks the central nervous system, leading to recurrent relapses, blindness, paralysis, and even premature death. Aquaporin 4 Antibodies (AQP4-IgG) are identified as the primary cause of NMOSD. The diagnosis of NMOSD involves various tests, including MRI scans, Anti aquaporin 4 immunoglobulinG, AQP4 IgG biomarker, CSF analysis, and the detection of AQP4-IgG biomarker. Currently, there are several therapeutic options available for NMOSD, including Plasma Exchange Therapy, Parenteral Injections of monoclonal antibody drugs like Satralizumab, Ocrevus, Bevacizumab, Rituximab, Eculizumab, Inebilizumab, Tocilizumab, and Corticosteroids.

Additionally, Immunoglobulin Therapy and C5 Protein Inhibitors are also used to manage the symptoms. NMOSD affects a significant patient population, with Europe having the highest prevalence. The European Medicines Agency has approved several drugs for the treatment of NMOSD, including Genentech's Enspryng and Alexion Pharmaceuticals' ULTOMIRIS. Homecare and Retail Pharmacy are becoming increasingly popular channels for the distribution of these therapies. The healthcare expenditures for NMOSD are substantial due to the high cost of these therapies and the need for long-term management. Insurance coverage and healthcare professional education play a crucial role in ensuring access to these therapies. The market for NMOSD therapeutics is expected to grow significantly in the coming years due to the increasing number of approved drugs and the rising awareness of the disease. The SARS CoV 2 virus has disrupted the healthcare system, leading to delays in the diagnosis and treatment of NMOSD. It is essential to prioritize the diagnosis and treatment of NMOSD to prevent irreversible damage and improve patient outcomes. Alpha1 antitrypsin is a crucial protein studied in the field of patient epidemiology for its role in various diseases. The National Center for Biotechnology Information provides extensive data on conditions such as multiple sclerosis, where biomarkers like anti-aquaporin 4 immunoglobulin G (AQP4 IgG) are vital for diagnosis. The Committee for Medicinal Products evaluates therapies including monoclonal antibodies, which are designed to target specific biomarkers like AQP4 IgG. These treatments are essential for managing autoimmune conditions and other complex diseases. Research and clinical advancements continue to evolve, highlighting the importance of biomarkers and targeted therapies in improving patient outcomes and understanding disease mechanisms.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the neuromyelitis optica spectrum disorder market between 2023 and 2027
• Precise estimation of the size of the neuromyelitis optica spectrum disorder market and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Vendor landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on vendor position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the industries competitive landscape and detailed information about industries
• Comprehensive analysis of factors that will challenge the growth of neuromyelitis optica spectrum disorder market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch